Cancer in patients with psoriasis

Halprin, Kenneth M.; Comerford, Mary; Taylor, J. Richard

doi:10.1016/s0190-9622(82)70144-6

Cited by 31 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Halprin et al ., 11 in 1981, retrospectively studied 150 psoriasis patients admitted to their hospital between 1976 and 1980. Using patients with diabetes admitted to the hospital during the same time period as a control, the number of skin cancers in both groups was assessed with an average follow‐up of 6.8 years.…”

Section: Resultsmentioning

confidence: 99%

UVB phototherapy and skin cancer risk: a review of the literature

2005

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

UVB phototherapy and skin cancer risk: a review of the literature

2005

View full text Add to dashboard Cite

show abstract

“…Possible induction of skin cancer has been a subject of major concern since the introduction of mustine treatment for mycosis fungoides (in 1956), psoriasis (in 1959), and LCH (in 1975) 826 27 After a latency period of two to seven years following topical mustard, increased rates (two- to ninefold) of epithelial cancers (basal cell carcinoma, squamous cell carcinoma, actinic keratoses, or keratoakanthoma) were reported in patients both with mycosis fungoides12 13 15 17 18 and psoriasis 1416 Because of a previous report suggesting that ultraviolet B photocarcinogenesis was increased by mustine,11 sun protection seems to be advisable during and after treatment, but skin tumours were also reported in areas not exposed to the sun, and both in areas with and without previous mustine treatment.…”

Section: Discussionmentioning

confidence: 99%

Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis

Hoeger

Nanduri²,

Harper³

et al. 2000

Archives of Disease in Childhood

View full text Add to dashboard Cite

Background and objectives-Skin lesions in Langerhans cell histiocytosis (LCH) are often painful and diYcult to treat. Topical application of nitrogen mustard (0.02% mechlorethamine hydrochloride, mustine), an alkylating cytostatic agent, has been shown to be eVective. There is, however, concern about potentially harmful long term side eVects. Study design-In a retrospective study 20 children with LCH (average extent of initial skin involvement: 16.4% body surface) were followed up for an average of 8.3 years after completion of topical mustine therapy. They had received a total of 34 courses (mean duration 14.2 weeks) of topical mustine. Disease status on follow up was assessed according to the Histiocyte Society classification. Results-After mustine was introduced, 16 patients were able to discontinue systemic steroids and/or chemotherapy. Topical mustine was well tolerated in 18 patients, but two developed irritant dermatitis. On follow up, the disease was inactive in 10 patients. Among the children with active disease, six had mild skin disease and four had progressive disease, two of them with skin lesions unresponsive to mustine treatment. Scars confined to areas of formerly active skin disease were found in six patients. There was no evidence of premalignant or malignant skin disease in the treated areas. Conclusion-Topical mustine is an eVective and safe treatment for skin disease in most children with LCH. Residual scarring was probably a result of the disease itself rather than to mustine. Although no evidence of skin cancer was found in this study, continued long term follow up is advisable. (Arch Dis Child 2000;82:483-487)

show abstract

“…4,5,8 As multiple treatments, all potentially carcinogenic, are often used in patients with psoriasis, this may explain that the other studies did not show a protective effect of psoriasis. 6,7,10 To calculate the long-term excess costs of NMSC due to UV-B phototherapy, the purpose of the present study was to quantify the dose-response relation of UV-B monotherapy to NMSC incidence. Because none of the studies gave appropriate information about the risk of NMSC as a function of the time since first exposure and/or the dose of the exposure, it is impossible to construct a valid dose-response relation from their results.…”

Section: Summary and Discussion Of The Datamentioning

confidence: 99%